BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 26817873)

  • 1. Makorin Ring Finger Protein 1 as Adjunctive Marker in Liquid-based Cervical Cytology.
    Lee M; Chang MY; Shin HY; Shin E; Hong SW; Kim KM; Chay DB; Cho H; Kim JH
    Medicine (Baltimore); 2016 Jan; 95(3):e2425. PubMed ID: 26817873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program.
    Gustinucci D; Passamonti B; Cesarini E; Butera D; Palmieri EA; Bulletti S; Carlani A; Staiano M; D'Amico MR; D'Angelo V; Di Dato E; Martinelli N; Malaspina M; Spita N; Tintori B; Fulciniti F
    Acta Cytol; 2012; 56(5):506-14. PubMed ID: 23075891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.
    El-Zein M; Gotlieb W; Gilbert L; Hemmings R; Behr MA; Franco EL;
    Int J Cancer; 2021 Jan; 148(2):492-501. PubMed ID: 32781481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical value of p16
    Song FB; Du H; Xiao AM; Wang C; Huang X; Yan PS; Liu ZH; Qu XF; Belinson JEROMEL; Wu RF
    Zhonghua Fu Chan Ke Za Zhi; 2020 Nov; 55(11):784-790. PubMed ID: 33228350
    [No Abstract]   [Full Text] [Related]  

  • 5. Combined use of cytology, p16 immunostaining and genotyping for triage of women positive for high-risk human papillomavirus at primary screening.
    Cuzick J; Adcock R; Carozzi F; Gillio-Tos A; De Marco L; Del Mistro A; Frayle H; Girlando S; Sani C; Confortini M; Zorzi M; Giorgi-Rossi P; Rizzolo R; Ronco G;
    Int J Cancer; 2020 Oct; 147(7):1864-1873. PubMed ID: 32170961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical value of fully automated p16/Ki-67 dual staining in the triage of HPV-positive women in the Norwegian Cervical Cancer Screening Program.
    Ovestad IT; Dalen I; Hansen E; Loge JL; Dybdahl BM; Dirdal MB; Moltu P; Berland JM
    Cancer Cytopathol; 2017 Apr; 125(4):283-291. PubMed ID: 27918650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.
    Uijterwaal MH; Polman NJ; Witte BI; van Kemenade FJ; Rijkaart D; Berkhof J; Balfoort-van der Meij GA; Ridder R; Snijders PJ; Meijer CJ
    Int J Cancer; 2015 May; 136(10):2361-8. PubMed ID: 25345358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of p16/Ki-67 dual staining in detection of cervical precancer and cancers: a multicenter study in China.
    Yu LL; Chen W; Lei XQ; Qin Y; Wu ZN; Pan QJ; Zhang X; Chang BF; Zhang SK; Guo HQ; Qiao YL
    Oncotarget; 2016 Apr; 7(16):21181-9. PubMed ID: 27029033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The sensitivity and specificity of p16(INK4a) cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL pap cytology results.
    Denton KJ; Bergeron C; Klement P; Trunk MJ; Keller T; Ridder R;
    Am J Clin Pathol; 2010 Jul; 134(1):12-21. PubMed ID: 20551261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the sensitivity and specificity of p16/Ki-67 dual staining and HPV DNA testing of abnormal cervical cytology in the detection of histology proven cervical intraepithelial neoplasia grade 2 and above (CIN 2+).
    Tay TKY; Lim KL; Hilmy MH; Thike AA; Goh ST; Song LH; Hwang JSG; Mantoo S
    Malays J Pathol; 2017 Dec; 39(3):257-265. PubMed ID: 29279588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population.
    Wentzensen N; Schwartz L; Zuna RE; Smith K; Mathews C; Gold MA; Allen RA; Zhang R; Dunn ST; Walker JL; Schiffman M
    Clin Cancer Res; 2012 Aug; 18(15):4154-62. PubMed ID: 22675168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p16 Immunohistochemistry is useful in confirming high-grade squamous intraepithelial lesions (HSIL) in women with negative HPV testing.
    Zhang G; Yang B; Abdul-Karim FW
    Int J Gynecol Pathol; 2015 Mar; 34(2):180-6. PubMed ID: 25675189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnostic value of p16/mcm2 dual staining in cervical intraepithelial neoplasia and its association with high-risk HPV infection].
    Wang HR; Liao GD; Jiang Y; Li YC; Qiao YL; Chen W
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Sep; 38(9):1241-1245. PubMed ID: 28910940
    [No Abstract]   [Full Text] [Related]  

  • 15. Cytology versus HPV testing for cervical cancer screening in the general population.
    Koliopoulos G; Nyaga VN; Santesso N; Bryant A; Martin-Hirsch PP; Mustafa RA; Schünemann H; Paraskevaidis E; Arbyn M
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008587. PubMed ID: 28796882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
    Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
    Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
    [No Abstract]   [Full Text] [Related]  

  • 17. Liquid-based cytology--new possibilities in the diagnosis of cervical lesions.
    Juric D; Mahovlić V; Rajhvajn S; Ovanin-Rakić A; Skopljanac-Macina L; Barisić A; Projić IS; Babić D; Susa M; Corusić A; Oresković S
    Coll Antropol; 2010 Mar; 34(1):19-24. PubMed ID: 20432728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of p16/Ki-67 in ASC-US/LSIL or Normal Cytology with Presence of Oncogenic HPV DNA.
    Solares C; Velasco J; Álvarez-Ruiz E; González-Fernández L; Encinas AI; Astudillo A; Schneider J
    Anticancer Res; 2015 Nov; 35(11):6291-5. PubMed ID: 26504065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience of Combined Liquid Based Cervical Cytology and High-Risk HPV mRNA for Cervical Cancer Screening in Thammasat University Hospital.
    Muangto T; Chanthasenanont A; Lertvutivivat S; Nanthakomon T; Pongrojpaw D; Bhamarapravatana K; Suwannarurk K
    Asian Pac J Cancer Prev; 2016; 17(9):4409-4413. PubMed ID: 27797253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combining high-risk human papillomavirus DNA test and cytological test to detect early cervical dysplasia].
    Qian DY; Cen JM; Wang D; Zeng RH; Lin AH; Shu YH; Hong DH; Huang ZH
    Zhonghua Fu Chan Ke Za Zhi; 2006 Jan; 41(1):34-7. PubMed ID: 16635326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.